<DOC>
	<DOC>NCT01098877</DOC>
	<brief_summary>The study will evaluate the hypothesis that at doses and plasma concentrations which affect pharmacodynamic markers of activity at the chemokine receptors, CCR2 and CCR5, the compound is safe and well tolerated. It will also evaluate the hypothesis that the pharmacokinetic profile is robust and consistent with a once or twice a day therapeutic administration.</brief_summary>
	<brief_title>First In Human Study Of Increasing Oral Doses Of PF-04634817</brief_title>
	<detailed_description />
	<criteria>Healthy male or female (of nonchild bearing potential) subjects between 18 and 55 years of age. Body mass index of 17.5 to 30.5 kg/m2 and total body weight &gt; 50kg. Evidence or history of any clinically significant disease. Treatment with an investigational drug within 30 days of study start Use of prescription and nonprescription medicines within 7 days of study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Phase1</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>toleration</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>